Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus SODIUM PHOSPHATE P 32.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus SODIUM PHOSPHATE P 32.
HIPPURAN I 131 vs SODIUM PHOSPHATE P 32
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
Sodium phosphate P 32 is a radioactive isotope that emits beta particles, causing ionization and subsequent cell death, particularly in rapidly dividing cells. It is incorporated into DNA and RNA, concentrating in tissues with high metabolic activity such as bone marrow and neoplastic cells.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
Intravenous administration: 1.5 mCi (55.5 MBq) per 70 kg body weight, single dose. For polycythemia vera, oral dose: 3-5 mCi (111-185 MBq) as a single dose. Frequency is one-time or as needed based on response.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Terminal elimination half-life: 14.3 days (range 13-16 days). Clinically relevant for bone marrow suppression monitoring; cumulative effect over multiple doses.
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: ~40% within 24 hours via glomerular filtration; Fecal: ~60% over 1-2 weeks as unabsorbed or secreted into bile. Total elimination approaches 100% after 2 weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical